UCB SA ADR (UCBJY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

UCB SA ADR (UCBJY) returned 0.00% year-to-date (YTD) and 0.00% over the past 12 months. Over the past 10 years, UCBJY returned 0.00% annually, underperforming the S&P 500 benchmark at 10.35%.

The table below presents the monthly returns of UCBJY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.

With an overall rank of 82, UCBJY is among the top 18% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.

The charts below present risk-adjusted performance metrics for UCB SA ADR (UCBJY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.

There isn't enough data available to calculate the Sharpe ratio for UCB SA ADR. This metric is based on the past 12 months of trading data. Please check back later for updated information.

UCB SA ADR provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.79 per share.

The table displays the monthly dividend distributions for UCB SA ADR. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the UCB SA ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the UCB SA ADR was 4.10%, occurring on May 31, 2012. Recovery took 2 trading sessions.

The current UCB SA ADR drawdown is 3.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of UCB SA ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The chart presents the Earnings Per Share (EPS) performance of UCB SA ADR, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -8.4%.

The Valuation section provides an overview of how UCB SA ADR is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.